Service Quote Request
Please fill out the form below with your detailed inquiry.
-
PHONE: 1-866-918-6812
Gene Knock-ins & Knock-outs
SignaGen enables advanced genomic engineering through the delivery of donor DNA templates and site-specific recombinase or nuclease-based editing systems. Using its In Vivo Grade viral vector production platform, researchers can achieve stable and precise genomic modifications with high reproducibility. All custom genome-editing projects are supported by rigorous quality control (QC) metrics to ensure consistency and reliability for longitudinal and translational studies.
Adenovirus (AdV), adeno-associated virus (AAV), and lentivirus (LV) represent the three principal viral delivery systems for genome editing, each offering distinct advantages for gene knock-out (KO) and knock-in (KI) applications based on genome persistence and cargo capacity. Lentivirus is the gold standard for generating stable cell lines, as its permanent integration into the host genome enables durable CRISPR/Cas9-mediated gene disruption and heritable transmission of edits to daughter cells. In contrast, AAV is the preferred platform for in vivo precision editing and therapeutic knock-in applications; its single-stranded DNA genome promotes homology-directed repair (HDR), thereby enhancing the efficiency of precise gene insertion, although its packaging capacity is limited to approximately 4.7 kb. Adenovirus addresses applications requiring large genetic payloads and transient expression: its high cargo capacity (approximately 8 kb for helper-dependent vectors) supports delivery of bulky editing systems such as Prime Editors and large donor templates, while its episomal, non-integrating profile enables a “hit-and-run” strategy that minimizes long-term nuclease expression and reduces the risk of off-target genomic alterations.
| Vector | Genome Behavior | Best Use Case (KI/KO) | Key Advantage |
| Lentivirus | Integrating (Random) | Permanent KO in dividing cells; CRISPR libraries. | modification persists in all daughter cells (Stable). |
| AAV | Non-integrating (mostly) | Precise KI in vivo; HDR-mediated repair. | ssDNA genome boosts Knock-in efficiency; low immunogenicity. |
| Adenovirus | Non-integrating (Episomal) | Transient Delivery of Cas9/gRNA; Large Donor KI. | “Hit-and-run” editing (reduces off-target risks); Huge cargo size. |
Off-the-shelf viral vector tools transgene knock-ins & knock-outs
| SKU # | Viral Vector | Unit Size | Titer |
|---|---|---|---|
| SL101136 | AAV1-CMV-SaCas9-U6-gRNA(SCRM) | 10 ~ 30 µL | >1E+13 VG/mL |
| SL101137 | AAV9-CMV-saCas9-U6-gRNA(SCRM) | 10 ~ 30 µL | >1E+13 VG/mL |
| SL101404 | AAV9-CMV-hSpCas9 | 10 ~ 30 µL | >1E+13 VG/mL |
| SL101465 | AAV8-CMV-saCas9-U6-gRNA(SCRM) | 10 ~ 30 µL | >1E+13 VG/mL |
| SL116041 | AAV9-CMV-SaCas9 | 10 ~ 30 µL | >1E+13 VG/mL |
| SL116042 | AAV9-Syn-SaCas9 | 10 ~ 30 µL | >1E+13 VG/mL |
| SL116043 | AAV1-CMV-SaCas9 | 10 ~ 30 µL | >1E+13 VG/mL |
| SL116044 | AAV1-Syn-SaCas9 | 10 ~ 30 µL | >1E+13 VG/mL |
| SL116046 | AAV1-Mecp2-SpCas9(D10A) | 10 ~ 30 µL | >1E+13 VG/mL |
| SL116047 | AAV2-Mecp2-SpCas9(D10A) | 10 ~ 30 µL | >1E+13 VG/mL |
| SL116048 | AAV9-Mecp2-SpCas9(D10A) | 10 ~ 30 µL | >1E+13 VG/mL |
| SL101404 | AAV9-miniCMV-SpCas9 | 10 ~ 30 µL | >1E+13 VG/mL |
| SL116408 | AAV9-Syn-SaCas9 | 10 ~ 30 µL | >1E+13 VG/mL |
| SL100307 | LV-EF1α-SpCas9 | 25 ~ 50 µL | >1E+9 TU/mL |
| SL100310 | LV-CMV-SpCas9 | 25 ~ 50 µL | >1E+9 TU/mL |
| SL101106 | Ad-CMV-SpCas9 | 50 ~ 200 µL | >1E+10 PFU/mL |
| SL101107 | Ad-CMV-Cas9(D10A)-T2A-DasherGFP | 50 ~ 200 µL | >1E+10 PFU/mL |
| SL101713 | Ad-CMV-SaCas9 | 50 ~ 200 µL | >1E+10 PFU/mL |
| SL101714 | Ad-CMV-SaCas9-CMV-GFP | 50 ~ 200 µL | >1E+10 PFU/mL |
| SL101751 | Ad-CMV-3xFLAG-SpCas9-P2A-PuroR | 50 ~ 200 µL | >1E+10 PFU/mL |
Interested in custom viral vectors for gene knock-ins & knock-outs?
SignaGen offers end-to-end viral vector solutions for precise genome editing. We design and produce AAV, lentiviral, and adenoviral vectors for CRISPR applications, including delivery of Cas nucleases, gRNAs, and donor templates. With optimized designs, high-titer production, and rigorous QC, we support efficient genome modification across in vitro, in vivo, and preclinical models.
Important updates waiting for you!
Enter your email address below and subscribe to our newsletter